<p><strong>Tilray Brands (纳斯达克: TLRY)</strong> 将于今天市场收盘后发布 2025 财年第四季度财报。这家大麻和饮料公司在应对波动的终端市场的同时，正在执行向更高利润率的国际医疗大麻和饮料整合的战略转型。该报告的重要性在于，它将检验 Tilray 的成本削减、全球分销规模和多元化投资组合是否能够使业务恢复盈利增长。随着德国医疗合法化、美国饮料扩张和 THC 创新的推进，投资者将关注利润率、现金消耗和 2026 财年的前景。</p>
<h2>华尔街的预测</h2>
<p>季度估计：</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<p>– 收入：2.3329 亿美元</p>
<p>– 每股收益（标准化）：$0.00</p>
<p>2025 财年全年共识估计：</p>
<p>– 2025 财年收入：8.3032 亿美元</p>
<p>– 2025 财年每股收益：-$0.02</p>
<p>这代表着与 2024 财年收入 8.43 亿美元相比，收入略有下降（-1.5%），而每股收益则较 2024 财年的-$0.16 有所改善。</p>
<h2>今晚关注的五个关键点</h2>
<p><strong>国际医疗大麻的势头</strong></p>
<p>管理层强调德国、意大利和波兰在第三季度的强劲增长，德国合法化后花卉销售同比增长 79%。Tilray 正在积极重新分配供应到德国，以获取更高的利润率。</p>
<p><strong>项目 420 整合与饮料战略</strong></p>
<p>饮料的毛利率在第三季度扩大至 36%，但由于 SKU 合理化，收入表现平淡。分析师将关注高潜力品牌如 Shock Top、SweetWater 和 Montauk 的稳定迹象和增量增长。</p>
<p><strong>大麻衍生 THC 和健康渠道的增长</strong></p>
<p>Tilray 目前在美国 10 个州和 1000 家商店分销大麻衍生的 THC 饮料。管理层将其视为一个数百万美元的机会，如果联邦法规朝有利方向发展，潜在收益将更大。</p>
<p><strong>现金流和盈利能力的纪律</strong></p>
<p>尽管调整后的每股收益接近盈亏平衡，投资者将仔细审查现金流的使用情况，第三季度为-$580 万，以及管理层减少资本支出、法律和解和营运资金拖累的能力。</p>
<p><strong>加拿大大麻市场份额的权衡</strong></p>
<p>Tilray 因利润驱动的决策而减少低利润率的电子烟和预卷产品，导致加拿大销售受到影响。任何关于销量趋势或市场份额恢复的更新将是建模 2026 财年增长的关键。</p>
<h2>Tilray Brands 在最近季度财报发布后的表现</h2>
<p>尽管 Tilray 已连续四个季度超出每股收益预期，但该股的反应却不一致——除非与战略清晰度相关，否则波动较小。</p>
<table>
<thead>
<tr>
<th>季度</th>
<th>每股收益意外</th>
<th>1 日变动</th>
<th>7 日变动</th>
<th>14 日变动</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025 财年第三季度</td>
<td>+0.03</td>
<td>-0.4%</td>
<td>+2.0%</td>
<td>+0.9%</td>
</tr>
<tr>
<td>2025 财年第二季度</td>
<td>+0.01</td>
<td>-3.5%</td>
<td>-6.8%</td>
<td>-7.2%</td>
</tr>
<tr>
<td>2025 财年第一季度</td>
<td>+0.02</td>
<td>-1.6%</td>
<td>-2.4%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>2024 财年第四季度</td>
<td>+0.05</td>
<td>+7.9%</td>
<td>+5.4%</td>
<td>+8.7%</td>
</tr>
</tbody>
</table>
<p>本篇文章《财报直播：Tilray Brands (TLRY) 第四季度完整报道》首发于 24/7 Wall St..</p>

TLRY

<p>Tilray Brands（纳斯达克代码：TLRY）今天将公布其 2025 财年第四季度的财报，重点关注其向更高利润率的国际医疗大麻和饮料整合的战略转变。值得关注的关键指标包括 233.29 百万美元的收入预期和每股收益为 0.00 美元。投资者将密切关注现金流、盈利能力以及在加拿大市场份额的恢复，尤其是在最近的每股收益超预期之后。该公司在德国的表现及其饮料战略对于未来的增长预测也将至关重要</p>

<p><strong>Tilray Brands (Nasdaq: TLRY)</strong> reports Q4 fiscal 2025 earnings after the market closes today. The cannabis and beverage company has been navigating volatile end-markets while executing a strategic shift toward higher-margin international medical cannabis and beverage consolidation. This report matters as it will test whether Tilray’s cost-cutting, global distribution scale, and diversified portfolio can return the business to profitable growth. With Germany’s medical legalization, U.S. beverage expansion, and THC innovation in play, investors will be focused on margins, cash burn, and FY26 outlook.</p>
<div class="lb-trans"><p><strong>Tilray Brands (纳斯达克: TLRY)</strong> 将于今天市场收盘后发布 2025 财年第四季度财报。这家大麻和饮料公司在应对波动的终端市场的同时，正在执行向更高利润率的国际医疗大麻和饮料整合的战略转型。该报告的重要性在于，它将检验 Tilray 的成本削减、全球分销规模和多元化投资组合是否能够使业务恢复盈利增长。随着德国医疗合法化、美国饮料扩张和 THC 创新的推进，投资者将关注利润率、现金消耗和 2026 财年的前景。</p>
</div><h2>What Wall Street Projects</h2>
<div class="lb-trans"><h2>华尔街的预测</h2>
</div><p>Quarterly estimates:</p>
<div class="lb-trans"><p>季度估计：</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<p>– Revenue: $233.29 million</p>
<div class="lb-trans"><p>– 收入：2.3329 亿美元</p>
</div><p>– EPS (Normalized): $0.00</p>
<div class="lb-trans"><p>– 每股收益（标准化）：$0.00</p>
</div><p>Full-Year 2025 Consensus Estimates:</p>
<div class="lb-trans"><p>2025 财年全年共识估计：</p>
</div><p>– FY2025 Revenue: $830.32 million</p>
<div class="lb-trans"><p>– 2025 财年收入：8.3032 亿美元</p>
</div><p>– FY2025 EPS: -$0.02</p>
<div class="lb-trans"><p>– 2025 财年每股收益：-$0.02</p>
</div><p>This represents a slight decline in topline vs. FY2024’s $843 million (-1.5%) and a modest improvement from FY2024 EPS of -$0.16.</p>
<div class="lb-trans"><p>这代表着与 2024 财年收入 8.43 亿美元相比，收入略有下降（-1.5%），而每股收益则较 2024 财年的-$0.16 有所改善。</p>
</div><h2>5 Keys to Watch Tonight</h2>
<div class="lb-trans"><h2>今晚关注的五个关键点</h2>
</div><p><strong>International Medical Cannabis Momentum</strong></p>
<div class="lb-trans"><p><strong>国际医疗大麻的势头</strong></p>
</div><p>Management emphasized strong Q3 growth in Germany, Italy, and Poland, with German flower sales up 79% YoY post-legalization. Tilray is actively reallocating supply to Germany due to higher margins.</p>
<div class="lb-trans"><p>管理层强调德国、意大利和波兰在第三季度的强劲增长，德国合法化后花卉销售同比增长 79%。Tilray 正在积极重新分配供应到德国，以获取更高的利润率。</p>
</div><p><strong>Project 420 Integration and Beverage Strategy</strong></p>
<div class="lb-trans"><p><strong>项目 420 整合与饮料战略</strong></p>
</div><p>Beverage gross margins expanded to 36% in Q3, but topline was muted due to SKU rationalization. Analysts will watch for signs of stabilization and incremental growth in high-potential brands like Shock Top, SweetWater, and Montauk.</p>
<div class="lb-trans"><p>饮料的毛利率在第三季度扩大至 36%，但由于 SKU 合理化，收入表现平淡。分析师将关注高潜力品牌如 Shock Top、SweetWater 和 Montauk 的稳定迹象和增量增长。</p>
</div><p><strong>Hemp-Derived THC and Wellness Channel Growth</strong></p>
<div class="lb-trans"><p><strong>大麻衍生 THC 和健康渠道的增长</strong></p>
</div><p>Tilray is now distributing hemp-derived THC drinks in 10 U.S. states and 1,000 stores. Management views this as a multimillion-dollar opportunity, with potential upside if federal regulation evolves favorably.</p>
<div class="lb-trans"><p>Tilray 目前在美国 10 个州和 1000 家商店分销大麻衍生的 THC 饮料。管理层将其视为一个数百万美元的机会，如果联邦法规朝有利方向发展，潜在收益将更大。</p>
</div><p><strong>Cash Flow and Profitability Discipline</strong></p>
<div class="lb-trans"><p><strong>现金流和盈利能力的纪律</strong></p>
</div><p>While adjusted EPS has hovered near breakeven, investors will scrutinize cash flow usage, which was -$5.8M in Q3, and management’s ability to reduce capex, legal settlements, and working capital drag.</p>
<div class="lb-trans"><p>尽管调整后的每股收益接近盈亏平衡，投资者将仔细审查现金流的使用情况，第三季度为-$580 万，以及管理层减少资本支出、法律和解和营运资金拖累的能力。</p>
</div><p><strong>Canadian Cannabis Market Share Trade-Offs</strong></p>
<div class="lb-trans"><p><strong>加拿大大麻市场份额的权衡</strong></p>
</div><p>Tilray’s margin-driven decision to shift away from lower-margin vape and pre-roll SKUs has hit Canadian sales. Any update on volume trends or market share recovery will be key to modeling FY2026 growth.</p>
<div class="lb-trans"><p>Tilray 因利润驱动的决策而减少低利润率的电子烟和预卷产品，导致加拿大销售受到影响。任何关于销量趋势或市场份额恢复的更新将是建模 2026 财年增长的关键。</p>
</div><h2>How Tilray Brands Performed After Recent Quarterly Earnings Releases</h2>
<div class="lb-trans"><h2>Tilray Brands 在最近季度财报发布后的表现</h2>
</div><p>While Tilray has delivered four straight EPS beats, the stock’s reaction has been inconsistent — with muted moves unless tied to strategic clarity.</p>
<div class="lb-trans"><p>尽管 Tilray 已连续四个季度超出每股收益预期，但该股的反应却不一致——除非与战略清晰度相关，否则波动较小。</p>
</div><table>
<thead>
<tr>
<th>Quarter</th>
<th>EPS Surprise</th>
<th>1-Day Move</th>
<th>7-Day Move</th>
<th>14-Day Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 FY2025</td>
<td>+0.03</td>
<td>-0.4%</td>
<td>+2.0%</td>
<td>+0.9%</td>
</tr>
<tr>
<td>Q2 FY2025</td>
<td>+0.01</td>
<td>-3.5%</td>
<td>-6.8%</td>
<td>-7.2%</td>
</tr>
<tr>
<td>Q1 FY2025</td>
<td>+0.02</td>
<td>-1.6%</td>
<td>-2.4%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Q4 FY2024</td>
<td>+0.05</td>
<td>+7.9%</td>
<td>+5.4%</td>
<td>+8.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>季度</th>
<th>每股收益意外</th>
<th>1 日变动</th>
<th>7 日变动</th>
<th>14 日变动</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025 财年第三季度</td>
<td>+0.03</td>
<td>-0.4%</td>
<td>+2.0%</td>
<td>+0.9%</td>
</tr>
<tr>
<td>2025 财年第二季度</td>
<td>+0.01</td>
<td>-3.5%</td>
<td>-6.8%</td>
<td>-7.2%</td>
</tr>
<tr>
<td>2025 财年第一季度</td>
<td>+0.02</td>
<td>-1.6%</td>
<td>-2.4%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>2024 财年第四季度</td>
<td>+0.05</td>
<td>+7.9%</td>
<td>+5.4%</td>
<td>+8.7%</td>
</tr>
</tbody>
</table>
</div><p>The post Earnings Live: Complete Tilray Brands (TLRY) 4Q Coverage appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>本篇文章《财报直播：Tilray Brands (TLRY) 第四季度完整报道》首发于 24/7 Wall St..</p>
</div>

收益直播：Tilray Brands（TLRY）第四季度的完整报道